Multi4器械门诊局部麻醉下管理复发性非肌层浸润性膀胱癌的首例人体研究
该研究通过猪模型预实验和首例人体前瞻性单臂试验,评估Multi4器械在门诊局部麻醉下处理复发性非肌层浸润性膀胱癌的可行性、安全性和诊断性能。结果显示92%的活检组织可评估,患者层面诊断率为89%,无器械相关不良事件,中位疼痛评分0.5/10,每次操作成本较经尿道膀胱肿瘤电切术降低73-89%。
要点
- Multi4在门诊局部麻醉下可完成复发性小NMIBC的活检和病灶管理,92%活检组织可评估。
- 无器械相关不良事件或Clavien-Dindo并发症,所有操作均未中转标准TUR-B。
- 中位疼痛评分0.5/10,每次操作成本较TUR-B降低73-89%。
核心结论
- Multi4可在局部麻醉下安全可行地完成门诊小复发性NMIBC的活检和病灶管理,诊断可靠且资源占用显著降低。
研究设计与样本
- 临床前在13头猪中进行体内评估,随后开展前瞻性、开放标签、单臂首例人体临床研究,纳入18例复发性Ta/T1 NMIBC(病灶≤10 mm)成人患者。
主要发现
- 猪模型共550次活检显示即刻止血且组织架构保留适合组织学评估,同一位置连续活检7-11次后发生穿孔。
- 临床共145次活检中134次(92%)可评估,达到主要终点,患者层面诊断率为89%。
- 无器械相关不良事件或Clavien-Dindo并发症,所有操作均在局部麻醉下完成,未中转标准TUR-B或使用额外器械。
- 中位疼痛评分为0.5/10,每次操作估计成本较TUR-B降低73-89%。
关键数值与推荐
- 主要终点为可评估活检比例,临床结果为134/145次(92%)。
- 患者层面诊断率为89%。
- 中位疼痛评分0.5/10(0-10量表)。
- 每次操作估计成本降低73-89%(对比TUR-B)。
临床怎么用
- 对于≤10 mm的复发性Ta/T1 NMIBC,可考虑在门诊局部麻醉下使用Multi4进行活检和病灶管理,以减少麻醉和医疗资源负担。
局限性
- 研究为单臂、开放标签、样本量小(18例),仅纳入≤10 mm的复发性Ta/T1病灶,需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the feasibility, safety and diagnostic performance of outpatient management of recurrent non-muscle-invasive bladder cancer (NMIBC) under local anaesthesia using the Multi4 instrument, a series of preclinical studies were performed followed by a first-in-human clinical investigation. NMIBC is associated with frequent recurrence, requiring repeated transurethral resection of the bladder (TUR-B) under anaesthesia, resulting in substantial healthcare burden. The Multi4 instrument integrates local anaesthesia injection, diathermy biopsy, coagulation and automated tissue retrieval. The primary objective was to determine whether Multi4 provides histologically evaluable biopsies in an outpatient setting, and secondary objectives included safety, usability, patient-reported outcomes and health-economic impact. METHODS: Preclinical in vivo evaluation was performed in 13 pigs to assess safety, biopsy quality, coagulation efficacy and perforation risk. A prospective, open-label, single-arm clinical investigation enrolled 18 adults with recurrent Ta/T1 NMIBC (≤10 mm lesions). Procedures were performed under local anaesthesia using flexible cystoscopy. The primary endpoint was the proportion of evaluable biopsies. Secondary endpoints included adverse events, usability, pain (0-10 scale), EQ-5D and cost comparison versus standard TUR-B. Diagnostic yield was also assessed at the patient level. RESULTS: A total of 550 porcine biopsies demonstrated immediate haemostasis and preserved tissue architecture suitable for histological assessment. Perforation occurred after 7-11 sequential biopsies at the same location, indicating a wide safety margin. Clinically, 134/145 biopsies (92%) were evaluable and the primary endpoint was met. Diagnostic yield per patient was 89%. No device-related adverse events or Clavien-Dindo complications occurred. All procedures were completed under local anaesthesia without conversion to standard TUR-B or use of additional instruments. The median pain score was 0.5/10. Estimated per-procedure cost reduction was 73-89% versus TUR-B. CONCLUSIONS: Multi4 enables feasible and safe outpatient biopsy and lesion management of small recurrent NMIBC under local anaesthesia with substantially reduced resource use while maintaining diagnostic reliability.
引用
- Melle-Hannah M, Kjölhede H, Bäckdahl H, et al. First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument. BJU Int. 2026. PMID: 42725722. doi:10.1111/bju.70445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。